Capesaris (GTx-758) / Oncternal Therap - LARVOL DELTA

Phase II, Dose Finding Study of GTx-758 (clinicaltrials.gov) - P2 | N=77 | Terminated | Sponsor: GTx | N=43 ➔ 77

Enrollment change • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer (clinicaltrials.gov) - P2; N=77; Completed; Sponsor: GTx; Active, not recruiting ➔ Completed

Clinical • Trial completion • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate Cancer. (PubMed, Clin Genitourin Cancer) - "GTx-758 has clinical activity for CRPC in a dose-dependent fashion. GTx-758 resulted in a reduction in hot flashes. On the basis of these findings, further clinical investigation of novel estrogen therapies is warranted."

Journal • P2 data • Cardiovascular • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer • Venous Thromboembolism • ER